Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Epilepsy 3Small Cell Lung Carcinoma 1Neuroblastoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × LY3295668 erbumine × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

NCT03898791 2021-08-05

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Eli Lilly and Company

Phase 1 Completed
48 enrolled
Thoracic

Epilepsy, Small Cell Lung Carcinoma

NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Eli Lilly and Company

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡